Thomas Trimarchi
Known title: President and COOCIK: 0002030813
Associated companies
Transaction History
| BBIO | ▼ Sell | Tax Withholding | 22,781 | $1.8M | 8/16/2026 | View on chart |
| BBIO | ▼ Sell | Open Market | 3,195 | $211K | 5/18/2026 | View on chart |
| BBIO | ▼ Sell | Open Market | 10,456 | $678K | 5/18/2026 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 22,781 | $1.5M | 5/16/2026 | View on chart |
| BBIO | ▲ Buy | Grant | 59,041 | $0 | 3/18/2026 | View on chart |
| BBIO | ▼ Sell | Open Market | 13,400 | $1.0M | 2/17/2026 | View on chart |
| BBIO | ▼ Sell | Open Market | 200 | $15K | 2/17/2026 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 18,819 | $1.4M | 2/16/2026 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 13,826 | $1.0M | 12/12/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 6,956 | $465K | 11/17/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 9,978 | $660K | 11/17/2025 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 21,317 | $1.4M | 11/16/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 42,237 | $2.1M | 8/21/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 15,380 | $771K | 8/18/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 1,973 | $101K | 8/18/2025 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 21,317 | $1.1M | 8/16/2025 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 21,317 | $721K | 5/16/2025 | View on chart |
| BBIO | ▲ Buy | Grant | 109,100 | $0 | 3/19/2025 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 13,782 | $481K | 2/16/2025 | View on chart |
| BBIO | ▲ Buy | Grant | 50,000 | $0 | 12/10/2024 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 17,936 | $425K | 11/16/2024 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 17,936 | $438K | 8/16/2024 | View on chart |
| BBIO | ▲ Buy | Grant | 19,003 | $0 | 8/6/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BridgeBio Reports Positive Phase 3 Data for Encaleret and Acoramidis
BridgeBio presented new data showing Encaleret improved symptoms in a Phase 3 trial for ADH1, with all participants reporting better outcomes than the standard of care. The company also shared real-world results for Acoramidis, indicating lower composite risk compared to tafamidis in ATTR-CM patients. These updates follow a recent 28% drop in the stock, which analysts suggest may be undervalued relative to their average target price.
BridgeBio Reports Positive Phase 3 Data for Encaleret and Acoramidis. BridgeBio presented new data showing Encaleret improved symptoms in a Phase 3 trial for ADH1, with all participants reporting better outcomes than the standard of care. The company also shared real-world results for Acoramidis, indicating lower composite risk compared to tafamidis in ATTR-CM patients. These updates follow a recent 28% drop in the stock, which analysts suggest may be undervalued relative to their average target price.